GlassScriptPhysician profile
Jeremy A Eckes
NPI 1437760949
$1,781.32
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $584 · 2023: $937 · 2024: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $416.93 | 2022-2023 | Briviact, Cimzia |
| Abbvie INC. | $313.33 | 2022-2024 | Botox |
| Horizon Therapeutics Plc | $227.29 | 2022-2023 | Uplizna |
| Atricure, INC. | $139.88 | 2023 | |
| Jazz Pharmaceuticals INC. | $102.54 | 2023 | |
| Emd Serono, INC. | $93.87 | 2023-2024 | Mavenclad |
| Neurocrine Biosciences, INC. | $83.71 | 2022-2024 | Ingrezza, Ongentys |
| Biogen, INC. | $56.20 | 2022 | |
| Corium, LLC | $48.15 | 2023 | Azstarys |
| Eisai INC. | $44.45 | 2023 | |
| Lilly USA, LLC | $38.59 | 2022-2023 | Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $26.10 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.51 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $25.25 | 2022 | |
| Sk Life Science, INC. | $24.32 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $23.53 | 2024 | Trodelvy |
| Argenx US, INC. | $21.80 | 2023 | Vyvgart |
| Ironshore Pharmaceuticals INC. | $15.65 | 2023 | Jornay Pm |
| Alexion Pharmaceuticals, INC. | $15.39 | 2023 | Ultomiris |
| Aquestive Therapeutics, INC. | $13.97 | 2022 | |
| Merz Pharmaceuticals, LLC | $12.70 | 2022 | |
| Livanova USA, INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Eckes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.